Last reviewed · How we verify
Cyclosporine Injection (IV)
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Severe rheumatoid arthritis, Severe psoriasis.
At a glance
| Generic name | Cyclosporine Injection (IV) |
|---|---|
| Also known as | Sandimmune |
| Sponsor | Berinstein, Jeffrey |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response, making it a potent immunosuppressant used to prevent organ rejection and treat autoimmune conditions.
Approved indications
- Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)
- Severe rheumatoid arthritis
- Severe psoriasis
- Nephrotic syndrome
- Autoimmune uveitis
Common side effects
- Nephrotoxicity/renal dysfunction
- Hypertension
- Tremor
- Gingival hyperplasia
- Hirsutism
- Headache
- Hyperkalemia
- Infection
- Neurotoxicity (encephalopathy)
Key clinical trials
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- TRACK-TBI Precision Medicine Part 3 - Option II (PHASE2)
- Optimizing PTCy Dose and Timing (PHASE1, PHASE2)
- A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy (PHASE1, PHASE2)
- A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy (PHASE3)
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis (PHASE4)
- Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
- Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine Injection (IV) CI brief — competitive landscape report
- Cyclosporine Injection (IV) updates RSS · CI watch RSS
- Berinstein, Jeffrey portfolio CI